Clinical trial · Observational
Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone
Combined Application of Lenalidomide and Desamethasone in the Palliative Therapy of Patients With Multiple Myeloma
NCT00911105CI-TRIAL-00033226REVLIMID-NIScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Purpose of this non-interventional study is the documentation of efficacy and safety data of multiple myeloma therapy with a combined treatment of Lenalidomide and Dexamethasone in daily routine practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients with multiple myeloma
- description
- Patients with multiple myeloma receiving second line therapy or higher.
Primary outcomes (1)
- measure
- Time to progression (TTP)
- timeFrame
- maximum 3 years per Patient
Secondary outcomes (8)
- measure
- Overall Response Rate
- timeFrame
- maximum 3 years per Patient
- measure
- Time to Treatment Discontinuation (TTD)
- timeFrame
- maximum 3 years per Patient
- measure
- Overall Survival (OS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with multiple myeloma with at least one previous therapy. * 18 years or older * Signed, written informed consent Exclusion Criteria: * Pregnancy or nursing * All other exclusion criteria listed in SmPC (summary of product characteristics)
References
Publications (0)
Data not yet available
No reference posted for this study.